Last updated: February 4, 2026
What is the case about?
Alcon Research, Ltd. filed patent infringement claims against Watson Laboratories, Inc. in the District of D. Colorado in 2017. The dispute centers on Watson’s alleged infringement of patents related to sustained-release ocular drug delivery devices. Specifically, Alcon asserts that Watson’s generic versions infringe patents covering proprietary formulations and delivery mechanisms used in Alcon’s branded products.
What are the key patents involved?
Alcon’s patent portfolio includes patents number US 8,127,174 and US 9,245,943, both issued for ocular drug delivery systems:
- US 8,127,174 – Discloses a sustained-release insert for delivering therapeutic agents to the eye.
- US 9,245,943 – Covers specific formulations and manufacturing processes for ocular inserts.
The patents aim to prevent competitors from entering the market with similar sustained-release ocular devices that could compete directly with Alcon’s commercial products.
What is the procedural history?
- Filing: Alcon filed the complaint on February 8, 2017, alleging patent infringement.
- Pleadings & Defenses:
- Watson denied infringement.
- Watson challenged the patents’ validity via petitions for inter partes review (IPR) at the Patent Trial and Appeal Board (PTAB).
- Inter Partes Review:
- Petition granted in 2018.
- PTAB invalidated the claims of US 8,127,174 in 2019; the decision of initial claim validity was in favor of Watson.
- District court proceedings:
- The litigation continued after IPR decisions.
- Alcon sought to pursue patent infringement claims despite PTAB’s invalidation of some claims.
- The case progressed through pre-trial motions, including motions to dismiss and summary judgment.
What are the major legal issues?
- Patent validity: Watson challenged the validity of the asserted patents through IPR, resulting in claims being invalidated.
- Infringement: Despite invalidation of some claims, Alcon maintains infringement of remaining claims or alternative formulations.
- Claim scope and patent enforceability: The case raises questions about the enforceability of patents after partial invalidation.
- Jurisdictional matters: The district court retained jurisdiction over the infringement claims despite PTAB invalidation.
What is the current status?
- Post-trial motions: The court has issued rulings on summary judgment. As of 2022, the court granted Watson’s motion for summary judgment of non-infringement for certain claims.
- Injunctions and damages: No injunction has been issued; damages are yet to be determined.
- Pending appeals: Alcon has filed motions to reconsider or appeal certain aspects related to patent scope and validity. The case remains active with ongoing appeals and potential further proceedings.
Legal and Market Implications
- Patent defense strength: The invalidation of key claims at PTAB weakens Alcon’s patent position but does not entirely nullify its intellectual property rights.
- Market competition: Watson's availability of generic ocular inserts could impact Alcon’s sales, with potential patent-infringement liability limits depending on claim scope.
- Litigation strategy: Companies may prioritize IPR proceedings to invalidate patents early, then pursue infringement litigation focusing on remaining valid claims or alternative formulations.
Analysis and Observations
- The case illustrates the complex interplay between district court litigation and PTAB proceedings, with invalidation of patent claims at PTAB potentially influencing, but not determinative of, legal outcomes in district court.
- The invalidation of claims reduces patent enforceability but does not prevent infringement claims based on surviving claims or non-patented formulations.
- Patent owners must continually monitor claim validity and consider strategic litigation and licensing to defend market share against generics.
- Watson’s success in PTAB highlights the importance of patent drafting that withstands validity challenges, particularly in filings related to pharmaceutical devices.
Key Takeaways
- The case exemplifies the evolving landscape of patent litigation intertwined with PTAB proceedings.
- Patent validity remains a pivotal factor, with IPRs often resulting in claim invalidation, impacting infringement lawsuits.
- In ocular drug delivery patents, innovation must be accompanied by robust claim scope to withstand validity challenges.
- Litigation outcomes can influence product launch timelines and market exclusivity periods.
- Patent challengers benefit from IPR proceedings for faster, cost-effective invalidation efforts, potentially reducing the value of incumbent patents.
FAQs
Q1: What is the primary legal basis for the infringement claim?
Alcon claims Watson’s generic ocular inserts infringe on its patents related to sustained-release delivery systems, primarily focusing on formulations and device architectures covered by US 8,127,174 and US 9,245,943.
Q2: How does PTAB invalidation affect district court patent infringement claims?
PTAB invalidation of patent claims reduces the scope of enforceable rights but does not automatically negate infringement allegations. Courts may still consider whether remaining valid claims are infringed.
Q3: Does patent invalidation at PTAB bar patent infringement litigation entirely?
No. Patent invalidation at PTAB applies only to the specific claims challenged. Remaining claims or different patent rights continue to support infringement claims.
Q4: What are the likely next steps in this case?
Prosecuting parties may pursue ongoing appeals or motions for reconsideration. Ongoing damages assessments or negotiations may follow if infringement is established.
Q5: How might this case influence future patent strategies in ocular drug delivery?
Patent owners should ensure claims are robust against validity challenges, incorporate broad and enforceable patent coverage, and proactively defend against potential IPRs.
Citations
[1] Patent Records: US 8,127,174; US 9,245,943.
[2] District of D. Colorado Case Docket: 1:17-cv-00252.
[3] PTAB decisions, IPR petitions, 2018-2019.
